Irene Teresa Molina-Martínez

Irene Teresa Molina-Martínez

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Journal of Controlled Release
Verified
Journal Article
Closed access
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
ARA.C. Rincón
A.C. Rincón
MAM. Alonso
M. Alonso
VRV. Reboto
V. Reboto
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
JRJose Carlos Rodriguez-Cabello
Jose Carlos Rodriguez-Cabello

1 September 2014 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
IBIrene Bravo-Osuna
Irene Bravo-Osuna
VAVanessa Andrés-Guerrero
Vanessa Andrés-Guerrero
MVMarta Vicario-De-La-Torre
Marta Vicario-De-La-Torre
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez

1 November 2011 in Journal of Controlled Release
Verified
Journal Article
Closed access
PCPatricia Checa-Casalengua
Patricia Checa-Casalengua
CJCaihui Jiang
Caihui Jiang
IBIrene Bravo-Osuna
Irene Bravo-Osuna
BTBudd Tucker
Budd Tucker
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell

27 April 2006 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
ARA.C. Rincón
A.C. Rincón
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
BPBeatriz De Las Heras Polo
Beatriz De Las Heras Polo
MAM. Alonso
M. Alonso
CBC. Baílez
C. Baílez
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell

8 May 2012 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
IBIrene Bravo-Osuna
Irene Bravo-Osuna
MNM. Noiray
M. Noiray
EBE. Briand
E. Briand
AWA. M. Woodward
A. M. Woodward
Pablo ArgüesoPablo Argüeso
Pablo Argüeso
GPG. Ponchel
G. Ponchel

7 February 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJosé López-Cano
José López-Cano
Sigen AsigenSigen Asigen
Sigen Asigen
VAVanessa Andrés-Guerrero
Vanessa Andrés-Guerrero
HTHongyun Tai
Hongyun Tai
IBIrene Bravo-Osuna
Irene Bravo-Osuna
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
The present study aims to develop a thermo-responsive-injectable hydrogel (HyG) based on PLGA-PEG-PLGA (PLGA = poly-(DL-lactic acid co-glycolic acid); PEG = polyethylene glycol) to deliver neuroprotective agents to the retina over time. Two PLGA-PEG PLGA copolymers with different PEG:LA:GA ratios (1:1.54:23.1 and 1:2.25:22.5) for HyG-1 and HyG-2 development respectively were synthetized and characterized by different techniques (gel permeation chromatography (GPC), nuclear magnetic resonance (NMR), dynamic light scattering (DLS), critical micelle concentration (CMC), gelation and rheological behaviour). According to the physicochemical characterization, HyG-1 was selected for further studies and loaded with anti-inflammatory drugs: dexamethasone (0.2%), and ketorolac (0.5%), alone or in combination with the antioxidants idebenone (1 µM) and D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) (0.002%). In vitro drug release and cytotoxicity studies were performed for the active substances and hydrogels (loaded and drug-free). A cellular model based on oxidative stress was optimized for anti-inflammatory and antioxidant screening of the formulations by using retinal-pigmented epithelial cell line hTERT (RPE-1). The copolymer 1, used to prepare thermo-responsive HyG-1, showed low polydispersity (PDI = 1.22) and a strong gel behaviour at 25% (w/v) in an isotonic buffer solution close to the vitreous temperature (31–34 °C). Sustained release of dexamethasone and ketorolac was achieved between 47 and 62 days, depending on the composition. HyG-1 was well tolerated (84.5 ± 3.2%) in retinal cells, with values near 100% when the anti-inflammatory and antioxidant agents were included. The combination of idebenone and dexamethasone promoted high oxidative protection in the cells exposed to H2O2, with viability values of 86.2 ± 14.7%. Ketorolac and dexamethasone-based formulations ameliorated the production of TNF-α, showing significant results (p ≤ 0.0001). The hydrogels developed in the present study entail a novel biodegradable tool to treat neurodegenerative processes of the retina overtime.